| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.82▼ | 1.79▲ | 1.79▲ | 1.76▲ | 1.79▲ |
| MA10 | 1.79▲ | 1.77▲ | 1.77▲ | 1.73▲ | 3.10▼ |
| MA20 | 1.77▲ | 1.76▲ | 1.76▲ | 1.70▲ | 5.06▼ |
| MA50 | 1.76▲ | 1.72▲ | 1.70▲ | 3.33▼ | 6.42▼ |
| MA100 | 1.68▲ | 1.59▲ | 1.73▲ | 5.19▼ | 9.69▼ |
| MA200 | 1.58▲ | 2.03▼ | 2.53▼ | 6.54▼ | 85.11▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.006▲ | 0.003▲ | 0.002▲ | 0.147▲ | -0.430▼ |
| RSI | 53.471▲ | 54.694▲ | 54.737▲ | 37.739▼ | 32.690▼ |
| STOCH | 88.730▲ | 62.222 | 62.222 | 73.392 | 4.175▼ |
| WILL %R | -26.667 | -26.667 | -26.667 | -10.000▲ | -93.412▼ |
| CCI | 42.535 | 71.553 | 71.553 | 77.575 | -73.730 |
|
Tuesday, September 22, 2026 04:54 PM
Longeveron Inc. (NASDAQ:LGVN) reported on September 16 that ELPIS II, its randomized Phase 2b trial in 40 infants with hypoplastic left heart syndrome, missed its primary efficacy endpoint. The study ...
|
|
Thursday, September 17, 2026 08:13 AM
Longeveron’s (NASDAQ: LGVN) September 16 announcement represents an important turning point for the company. The Phase 2b ELPIS II trial of laromestrocel in hypoplastic left heart syndrome, or HLHS, ...
|
|
Monday, March 16, 2026 06:21 AM
This article first appeared on GuruFocus. Longeveron Inc (NASDAQ:LGVN) is set to release its Q4 2025 earnings on Mar 17, 2026. The consensus estimate for Q4 2025 revenue is $0.15 million, and the ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 06/11/26 | 1.75 | 1.83 | 1.6991 | 1.81 | 38,834 |
| 05/11/26 | 1.80 | 1.8001 | 1.6575 | 1.71 | 34,442 |
| 04/11/26 | 1.76 | 1.82 | 1.75 | 1.78 | 61,400 |
| 03/11/26 | 1.71 | 1.80 | 1.71 | 1.78 | 38,108 |
| 02/11/26 | 1.74 | 1.79 | 1.655 | 1.71 | 58,475 |
| 30/10/26 | 1.78 | 1.80 | 1.5811 | 1.67 | 80,744 |
| 29/10/26 | 1.75 | 1.83 | 1.7307 | 1.75 | 62,767 |
| 28/10/26 | 1.74 | 1.83 | 1.70 | 1.78 | 77,660 |
| 27/10/26 | 1.62 | 1.76 | 1.62 | 1.73 | 90,730 |
| 26/10/26 | 1.55 | 1.86 | 1.50 | 1.605 | 90,942 |
|
|
||||
|
|
||||
|
|